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Background: Psychotherapies for psychosis typically aim to develop an awareness
of the implausible content of a delusion or target the underlying cognitive biases (i.e.,
problematic thinking styles, such as hasty decisions and illusory control) that foster
and maintain delusional beliefs. A recently designed individual-based treatment entitled
metacognitive therapy (MCT+) combines these two approaches. Emerging evidence
suggests individualized MCT+, when used concurrently with antipsychotic medication,
may be an effective psychological treatment for reducing delusional symptoms. However,
it remains to be tested whether MCT+ can be effective in patients with active delusions
who are not currently receiving psychotropic drugs.
Method: We present two cases (one patient with schizophrenia and the other with
delusional disorder) experiencing active delusions who underwent 4-weeks of intensive
MCT+, without concurrent antipsychotic medication (minimum 6-months unmedicated).
Baseline and 6-week follow-up data are presented on a variety of measures assessing
delusion symptom severity (i.e., PANSS, PSYRATS, SAPS), clinical insight, and cognitive
bias propensity.
Results: After 4-weeks of MCT+, both patients showed substantial reduction in
delusional symptoms, reported improved clinical insight, and were less prone to making
illusory correlations.
Conclusions: The presented case studies provide preliminary evidence for the feasibility
of MCT+ in treating patients not taking, or resistant to, antipsychotic medication.
Keywords: schizophrenia, psychotherapy, delusions, cognitive bias, CBT
Introduction
Antipsychotic medications are an effective treatment for the symptoms of psychosis, such as
delusions and hallucinations, and provide relief for many people with psychotic disorders.
However, many studies report that 20–30% of clients with psychosis do not respond to these
medications (Tandon, 2011; Leucht et al., 2012). Even when these treatments are effective, they are
often associated with only medium effect sizes relative to placebo, high levels of relapse, issues with
insight, and adherence, and serious side-effects (e.g., Leucht et al., 2009; Muench andHamer, 2010).
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Accordingly, interest in adjunctive non-pharmacological
treatments has gathered momentum in recent years. For
example, cognitive-behavioral therapy for psychosis (CBTp) is
now routinely administered alongside antipsychotic medications
to treat the core symptoms of psychosis (Lecomte et al., 2008;
Bechdolf et al., 2010; Morrison et al., 2014). CBTp aims to
identify and actively modify maladaptive delusional beliefs,
attitudes and behaviors often associated with psychosis, and
thereby helps clients to become aware of alternative explanations
and coping strategies (Steel, 2013). Reviews and meta-analyses of
its efficacy as an adjunct therapy to pharmacological treatments
have shown that CBTp adds small to medium effect sizes on
top of medication, and may represent an effective treatment
alternative for medication-resistant or non-adherent clients
(Wykes et al., 2008; Farhall and Thomas, 2013; Huhn et al.,
2014).
Built on the principles of CBTp, novel psychological
interventions for treating delusions are now starting to focus
on the underlying cognitive and social biases that contribute
to the formation and maintenance of delusional beliefs (Bell
et al., 2006; Balzan et al., 2012, 2013a,b; Garety and Freeman,
2013), rather than targeting the idiosyncratic delusions specific
to the individual client (Moritz et al., 2010b). One such
intervention is metacognitive training (MCT), which is a group-
based program consisting of eight intervention sessions (available
free of charge from www.uke.de/mkt). MCT is categorized under
six cognitive and social biases (i.e., attribution biases, jumping
to conclusions, belief inflexibility, overconfidence in errors,
theory of mind deficits, and depressive cognitive schemata).
The program attempts to raise the metacognitive awareness
of such biases within clients, thereby planting the “seeds of
doubt,” encouraging critical reflection, and ultimately reducing
the severity of delusional symptoms. Similar to CBTp, clinical
trials have consistently shown that MCT is effective in reducing
delusional symptoms relative to controls (Aghotor et al., 2010;
Moritz et al., 2011a, 2014a,b; Favrod et al., 2013), and exerts
sustained effects on the reduction of delusions over and above
the effects of antipsychotic medication (for an in-depth summary
and review of MCT see Balzan et al., 2014b; Moritz et al., 2014c).
In response to the emerging efficacy for the group-orientated
MCT program, an individually administered program entitled
“metacognitive therapy” (MCT+), has recently been developed.
This program combines the “process-oriented” approach of
the MCT group-training with elements of individual cognitive-
behavioral therapy for psychosis (CBTp). The combined
approach involves relating information from the original
MCT modules to the individual experiences, observations, and
symptoms of the individual client (Moritz et al., 2010a). MCT+
comprises a similar layout to the group-based MCT, and
covers the same six cognitive and social biases. However, the
individualized approach also includes opportunities for clients to
share their own personal experiences in relation to the material
being presented. This allows for a greater range of therapeutic
strategies, such as establishing therapy goals (e.g., reducing
paranoia in public spaces), reality testing (e.g., recalling certain
events in everyday life that could be regarded as clear evidence
for delusional ideas), and Socratic discussion (i.e., extensive
questioning to generate pros/cons and consequences of a
particular viewpoint). To date, the evidence for MCT+ is limited
to two small-scale studies (Moritz et al., 2011b; Balzan et al.,
2014a) and a single case report (Vitzthum et al., 2014), which
suggest that the therapy program is effective in significantly
reducing delusion severity and conviction, increasing clinical
insight, and improving performance on cognitive bias tasks.
Despite the demonstrated efficacy of CBTp, MCT, and
MCT+ in alleviating the symptoms of psychosis, few trials
have been able to test the efficacy of these psychotherapies in
the absence of antipsychotic medication. This is an important
clinical issue, as people with psychosis may become non-adherent
and discontinue taking antipsychotic treatment, or demonstrate
treatment resistance to these medications (Lieberman et al.,
2005). While at least one trial has been able to show the
efficacy of cognitive therapy in reducing psychiatric symptoms in
people with schizophrenia spectrum disorders who had chosen
not to take antipsychotic drugs (Morrison et al., 2014), more
reports are required. The purpose of the current paper is to
detail the case histories of two clients with psychosis (one
with schizophrenia and one with delusional disorder), neither
of whom were taking antipsychotic medication, but both had
received 4-weeks ofMCT+ as part of a larger randomized control
trial investigating the effectiveness of MCT+ in reducing the
symptoms of psychosis. MCT+ is a useful platform in order
to observe the efficacy of psychotherapies in the absence of
pharmacological treatment as it combines the approaches of both
CBTp and group-lead MCT, and therefore may be more effective
in reducing delusional symptoms than either treatment offered in
isolation.
Background
The following case study deals with two clients diagnosed
with a psychotic disorder, and who were experiencing active
delusions at the time of entering a larger randomized control
trial investigating the effectiveness of MCT+. Neither client was
taking antipsychotic medication (or any other psychotropic),
or receiving any other psychological therapy, at the time of
investigation (6-months unmedicated for Client 1; 9-months
unmedicated for Client 2), and both were outpatients living in
the community (for full summary of baseline symptoms, see
Table 1). Clinical insight was minimal for both clients.
Client 1
At the time of his involvement in the trial, Client 1 was a
20-year-old male who had been diagnosed with treatment-
resistant schizophrenia (limited success on trials of olanzapine,
ziprasidone, risperidone (oral and depot), pericyazine, and
quetiapine). He was diagnosed from a young age (records
indicate first diagnosis of schizophrenia was made at the age
of 14-years), with four psychiatric hospital admissions. He was
unemployed (receiving a government youth allowance) and was
living with a young family (two adults, two children under 5-
years) who had taken him in. He would otherwise have been
homeless. Pre-morbid IQ was estimated at 86 (using the WTAR;
see Design below).
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Psychiatric symptoms included vivid auditory hallucinations,
which he described as a number of male and female voices
that (i) commented on what he was doing or thinking, (ii)
made derogatory comments, and (iii) commanded him to
harm himself and others. He did not feel compelled to act
on the command hallucinations. He also experienced visual
hallucinations, including seeing floating facial parts in the dark.
His delusional beliefs included being persecuted by government
agencies who had been tracking him via secret cameras on his
street (which had recently increased in number), and a device
planted in his neck; he often had thoughts removing the device,
but worried about cutting his neck. He was a long-term frequent
user of THC (“1–2 bags per day” since he was 12 years old),
and was a heavy drinker (consuming approximately “10 liters of
wine and a carton of beer” weekly). Aggression, highly-impulsive
behavior (e.g., assaulting strangers), and psychiatric symptoms
intensified whilst taking either substance. A risk assessment
identified some occasional suicidal thoughts, but overall low risk,
with no definite motive or detailed plans. His treatment goals
included reducing his paranoia (e.g., leave the house at different
times) and conflicts with other people in his street (e.g., no longer
accusing them of persecution).
Client 2
Upon commencing the trial, Client 2 was 31-year-old male, with
delusional disorder (diagnosed 2 years prior), unemployed and
living on a disability support pension in a private boarding house.
He had at least two prior psychiatric hospital admissions. Client
2 had no history of auditory or visual hallucinations, did not
describe any current hallucinations, and did not drink alcohol or
use THC. Whilst very functional across a number of cognitive
domains, with above average intelligence (pre-morbid IQ was
estimated at 109), his paranoid delusional ideas have prevented
him from obtaining a stable career path, and reaching full social
independence.
His core paranoid delusion was that his personal identity and
details of his private life were readily available for people to
observe. His feeling of being “watched” first arose whilst working
in a large warehouse of approximately 400 employees, where
he suspected that he was being laughed at and talked about
behind his back. These ideas culminated with him confronting
the other employees about their knowledge of his personal life,
and his subsequent dismissal, whereby he moved across country
and relocated to another city in the hopes of escaping the
persecution. However, similar persecutory ideas persisted in his
new residence, with frequent thoughts that strangers were trying
to mess with his mind through social media and the internet, but
escalating to the belief that all computers were monitoring and
recording his actions and thoughts. He had previously sought
help from a psychotherapist with limited success, and hoped the
MCT+ sessions could help him to improve his ability to “test
reality” and thereby reduce his paranoia and ideas of persecution
in social settings.
Design
Both clients were randomized into the MCT+ treatment group
as part of a larger treatment trial that allocated participants
to either MCT+ or to cognitive remediation (active control
condition). The trial consisted of six sessions, consisting of
baseline assessment, four MCT+ sessions (covering all six
cognitive biases plus additional material), and a follow-up session
that mirrored the baseline measures, which was administered 1-
week after completing MCT+ (i.e., 1 month from commencing
the trial). Each of these six sessions lasted approximately 90–
120min. Clinical ethics was approved by the Human Ethics
Research Committee (TQEH/LMH/MH), Adelaide, Australia.
MCT+
Following the first baseline session, both clients commenced 4
weeks of MCT+, with one 90–120min session per week, usually
consisting of two MCT+ “units” per session. MCT+ consists
of ten units. Unit 1 is designed to build up the therapeutic
alliance and establish symptoms, which was not necessary
as these were established at the baseline session. Therefore,
the first therapy session combined a brief introduction to
MCT+ (Unit 2), generating an illness model (Unit 3), and
covered attributional styles (Unit 4), which specifically observed
the importance of considering multiple attributions (e.g.,
situational, personal, internal) jointly for a single event. The
second therapy session combined Unit 5 on decision-making,
which looks at the jumping to conclusions (JTC) bias and the
importance of gathering sufficient evidence before making a
decision, and Unit 6 on changing beliefs, which encourages
clients to re-evaluate the validity of their opinions and change
them when necessary, rather than always insisting on one’s
opinion and/or ignoring disconfirming evidence. The third
session covered Unit 7 on empathizing (e.g., the complexity
of social cues and the importance of collecting multiple social
cues before making strong social inferences) and Unit 8 on
overconfidence in memory errors. The final therapy session
focused on improving self-esteem and mood by looking that
factors that perpetuate depressive styles of thinking (Unit 9),
and concluded by looking at relapse prevention (Unit 10). For
an in-depth description of all MCT+ therapy units, please refer
to Balzan et al. (2014b) or by way of the following link: http://
www.clinical-neuropsychology.de/metacognitive-therapy-plus-
individualized-mct-for-psychosis.html.
Baseline and Follow-up Assessment
A number of assessments observing clinical and cognitive
domains were made as part of the larger trial. Only assessments
pertaining to the current case study are documented here. As
the principle aim of MCT+ is reduce the severity of delusional
ideation, a number of measures were included to assess
delusional propensity. Interview-led measures of delusional
severity included the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1987), which consists of seven positive,
seven negative, and 16 general psychotic symptoms; the Psychotic
Symptom Rating Scales (PSYRATS; Haddock et al., 1999), which
focuses on the frequency and duration of hallucination and
delusions; and the Scale for the Assessment of Positive Symptoms
(SAPS; Andreasen and Olsen, 1982), which covers a variety
of common hallucinatory and delusional themes (e.g., auditory
hallucinations, delusions of reference, persecutory delusions).
Clinical insight was estimated using the Schedule for Assessing
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TABLE 1 | Raw baseline and follow-up scores of symptom severity (PANSS; PSYRATS; SAPS; PDI-21), insight (SAI), and cognitive bias performance
(illusory control) for both clients.
Client 1 (schizophrenia) Client 2 (delusional disorder)
Baseline Follow-up Baseline Follow-up
SYMPTOM SEVERITY
PANSS (total) 89 80 65 46
PANSS-Delusions (P1) 6 5 5 3
PANSS-Positive 26 21 18 11
PANSS-Negative 16 15 17 9
PANSS-General 47 44 30 26
PSYRATS-Hallucinations 34 28 – –
PSYRATS-Delusions 23 20 18 12
SAPS-Hallucinations 23 19 – –
SAPS- Delusions 37 30 14 9
PDI-21-Global 281 243 83 58
PDI-21-Distress 77 74 23 17
PDI-Preoccupation 89 77 27 19
PDI-Conviction 95 75 25 15
INSIGHT
SAI 2 7 8 10
COGNITIVE BIAS TASK
Illusory control (%) 50 37.5 37.5 0
Illusory control: perceived connection (%) 50 37.5 50 12.5
PANSS, Positive and Negative Syndrome Scale; PSYRATS, Psychotic Symptom Rating Scales; SAPS, Scale for the Assessment of Positive Symptoms; PDI-21, 21-item Peters et al
Delusions Inventory; SAI, Schedule for Assessing Insight (higher scores indicate greater insight; max score = 18); illusory control task was completely non-contingent (i.e., any perceived
control >0 was interpreted as “illusory control”).
Insight (SAI) for psychosis patients (adapted from David, 1990).
The PANSS and PSYRATS interview-based assessments were
undertaken by a trained rater blind to treatment allocation
(i.e., this rater did not conduct the intervention). Additionally,
clients completed the self-report 21-item Peters et al Delusions
Inventory (PDI-21; Peters et al., 2004), which provides a scale
for global delusional ideation, and subscales for delusional
distress, preoccupation and conviction. Pre-morbid intelligence
was estimated by the Wechsler Test of Adult Reading (WTAR;
Wechsler, 2001).
The “illusion of control” bias, shown to be higher in delusional
samples (Balzan et al., 2013b), was assessed at baseline and
follow-up, consistent with a previous MCT+ efficacy study
that observed changes in this bias post-intervention (Balzan
et al., 2014a)1. Illusory control was assessed using a non-
contingent “tone task” adapted from Matute (1995). Participants
were presented with four buttons (labeled A, B, C, and D)
on a screen that could be activated using a mouse click, and
instructed that they would periodically hear a loud “tone”
noise (maximum duration 5-s), and that their task was to
find a way to stop it within this time by clicking the correct
combination of the four A, B, C, and D buttons. The task
comprised 40 trials of uncontrollable tones (i.e., all tones were
non-contingent on the participant’s response); 75% of tones
1Note: JTC was also assessed using the “beads task” (for a detailed overview, see
Fine et al., 2007), but neither client exhibited a “JTC bias” at baseline (i.e., definite
decision on first or second bead), so results of this task are not reported.
terminated automatically after 1-s (i.e., 30 trials appeared to
turn off after clicking buttons), and 25% terminated after 5-
s (i.e., 10 trials appeared to “max out”). After the 40 trials,
participants were asked to indicate the percentage of control they
had over the termination of tones, and the percentage of trials
in which the tones terminated because they had clicked on the
correct sequence of buttons (i.e., perceived response-outcome
connection).
Results
Table 1 summarizes the baseline and follow-up scores across
the clinical and cognitive measures of interest for both clients.
Symptom severity was reduced across all measures used. The
overall reductions in PANSS scores (Client 1: −9 points; Client
2: −19 points) were reflected in the positive subscale (Client
1:−5 points; Client 2:−7 points); importantly, there was modest
reduction in the delusions item (P1) specifically (Client 1: −1
point; Client 2: −2 points). This reduction in delusional severity
was mirrored by the both the PSYRATS (Client 1: −9 points;
Client 2: −19 points) and SAPS (Client 1: −7 points; Client
2: −5 points) delusions subscales, which take into account
the frequency, duration, distress, and level of conviction of
the delusional belief/s. Interestingly, both clients self-reported
reductions in delusional distress, preoccupation, and conviction
as evidenced by the PDI scale (Client 1:−38 points; Client 2:−25
points).
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Clinical insight was minimal in both clients at baseline (i.e.,
Client 1 scored 2 and Client 2 scored 8, out of a maximum score
of 18) but improved post-intervention, whereby both clients
started to doubt the validity/creditability of their beliefs, and
admitted the cause of their unusual experiences may be due to
internal causes (e.g., stress) rather than purely delusional causes
(e.g., chip inserted into neck). Client 1 also acknowledged the
potential role of THC in heightening the severity of his paranoia,
and was open to cutting down his usage, and even resuming
antipsychotic medication. Improvements were also observed for
the illusory control bias task, whereby both clients expressed
reduced perceived control over a non-contingent task (Client 2
correctly responded zero control at follow-up), and less perceived
“response-outcome” connection.
Discussion
The present case study reports the impact of individualized
metacognitive therapy (MCT+) in two clients with psychosis
(schizophrenia and delusional disorder), who were experiencing
active delusions, but were not receiving antipsychotic medication
at the time of the current trial. MCT+ aims to improve the well-
being of people living with psychosis, with a particular focus on
reducing the severity of delusional symptoms. MCT+ achieves
this by (1) bringing about an awareness of the underlying
cognitive biases or “traps” that are thought to contribute the
formation and maintenance of delusions, (2) offering clients
strategies to reduce their propensity to these biases, and (3)
relating the material to the personal experiences and belief
systems of the individual client.
The current findings suggest that MCT+ is effective in
reducing the symptoms of psychosis, and notably delusional
ideation, in the absence of antipsychotic medication. For both
clients, we observed overall improvements in positive symptoms
and delusional conviction, preoccupation, frequency, and level
of distress they caused (assessed by blind interviewer and self-
report). Clinical insight was still low at follow-up, but had
improved from baseline, and propensity to the illusion of
control bias was reduced. Of note, the illusion of control bias
is not specifically targeted in any of the MCT modules, which
suggests that MCT may be improving some underlying cognitive
mechanism that is responsible for a variety of cognitive biases
observed in psychosis (Balzan et al., 2014a). It is also worth
pointing out that neither client missed a single session (i.e., all
nine therapy units were covered over the 4-week therapy phase),
which highlights the ability of the therapy program to motivate
and actively engage with clients (even those with minimal
clinical insight), without being too confrontational or damaging
to the therapeutic alliance. The results also demonstrate that
the therapy program may be effective across multiple diagnoses
(i.e., the majority of MCT studies to date have mainly observed
schizophrenia or schizoaffective disorders), and different levels of
functioning (i.e., Client 2 had higher “above-average” pre-morbid
intelligence).
Overall, these findings are not only consistent with the
growing evidence-base for MCT (e.g., Moritz et al., 2014a),
but are also consistent with recent findings suggesting that
psychotherapy may be effective even in the absence of
antipsychotic medication or in treatment-resistant clients
(Morrison et al., 2014). Although the results of this case study
are promising, a number of methodological issues, common
to the majority of case studies, should be acknowledged. First,
the results should not be broadly generalized, and the reported
improvements may actually represent statistically non-significant
trends in the larger participant sample. Further hindering
generalization of the results is the lack of extended (e.g., 6-
month) follow-up data, which would provide evidence on the
sustainability of the reported improvements, and the SAPS
assessment was made by a rater who was aware of group
allocation. Neither client exhibited the typical JTC bias at baseline
(i.e., definite decision on two or less beads), which ruled out
the possibility of observing a reduction in JTC post-intervention.
Moreover, it is possible that the observed improvements may be
attributable to the natural fluctuations of psychotic symptoms
(“waxing and waning”) that occur across time, or to practice
effects in the illusion of control task. The results could also
reflect a more general effect of the therapeutic relationship. More
methodologically rigorous randomized control trials evaluating
the efficacy of MCT+ are required to properly address these
issues.
Concluding Remarks
Psychotherapeutic approaches in the treatment of psychosis have
been gaining ground in recent years, and have been shown to be
effective as adjunctive therapy when used alongside antipsychotic
medication, and represent a better treatment option when
added to antipsychotic therapy, than pharmacological therapy
alone. The therapeutic efficacy of psychotherapy in “treatment-
resistant” clients or where antipsychotic adherence is poor, is
much less well-understood. The current case study suggests that
individualized metacognitive therapy (MCT+), a combination of
the “process-oriented” approach of the MCT group-training and
individual cognitive-behavioral therapy for psychosis (CBTp),
may be an effective treatment option in such cases.
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